<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">39375177</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>07</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>10</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2056-5933</ISSN><JournalIssue CitedMedium="Internet"><Volume>10</Volume><Issue>4</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>07</Day></PubDate></JournalIssue><Title>RMD open</Title><ISOAbbreviation>RMD Open</ISOAbbreviation></Journal><ArticleTitle>Methotrexate treatment hampers induction of vaccine-specific CD4 T cell responses in patients with IMID.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">e004664</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1136/rmdopen-2024-004664</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">Methotrexate (MTX) is one of the most commonly used medications to treat rheumatoid arthritis (RA). However, the effect of MTX treatment on cellular immune responses remains incompletely understood. This raises concerns about the vulnerability of these patients to emerging infections and following vaccination.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">In the current study, we investigated the impact of MTX treatment in patients with immune-mediated inflammatory disease on B and CD4 T cell SARS-CoV-2 vaccination responses. Eighteen patients with RA and two patients with psoriatic arthritis on MTX monotherapy were included, as well as 10 patients with RA without immunosuppressive treatment, and 29 healthy controls. CD4 T and B cell responses were analysed 7 days and 3-6 months after two SARS-CoV-2 messenger RNA vaccinations. High-dimensional flow cytometry analysis was used to analyse fresh whole blood, an activation-induced marker assay to measure antigen-specific CD4 T cells, and spike probes to study antigen-specific B cells.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Seven days following two SARS-CoV-2 vaccinations, total B and T cell counts were similar between MTX-treated patients and controls. In addition, spike-specific B cell frequencies were unaffected. Remarkably, the frequency of antigen-specific CD4 T cells was reduced in patients using MTX and correlated strongly with anti-RBD IgG antibodies. These results suggest that decreased CD4 T cell activity may result in slower vaccination antibody responses in MTX-treated patients.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Taken together, MTX treatment reduces vaccine-induced CD4 T cell activation, which correlates with lower antibody responses.</AbstractText><AbstractText Label="TRIAL REGISTRATION NUMBER" NlmCategory="BACKGROUND">NL8900.</AbstractText><CopyrightInformation>© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Kummer</LastName><ForeName>Laura Y L</ForeName><Initials>LYL</Initials><Identifier Source="ORCID">0009-0008-1575-2973</Identifier><AffiliationInfo><Affiliation>Sanquin Research, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology and Neurophysiology, Amsterdam UMC Location AMC, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Fernández Blanco</LastName><ForeName>Laura</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Sanquin Research, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology and Neurophysiology, Amsterdam UMC Location AMC, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Kreher</LastName><ForeName>Christine</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Sanquin Research, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bos</LastName><ForeName>Amélie</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Sanquin Research, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kuijper</LastName><ForeName>Lisan H</ForeName><Initials>LH</Initials><AffiliationInfo><Affiliation>Sanquin Research, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Verstegen</LastName><ForeName>Niels J M</ForeName><Initials>NJM</Initials><AffiliationInfo><Affiliation>Sanquin Research, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van de Sandt</LastName><ForeName>Carolien E</ForeName><Initials>CE</Initials><AffiliationInfo><Affiliation>Sanquin Research, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, The Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Konijn</LastName><ForeName>Veronique A L</ForeName><Initials>VAL</Initials><AffiliationInfo><Affiliation>Sanquin Research, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duurland</LastName><ForeName>Mariël C</ForeName><Initials>MC</Initials><AffiliationInfo><Affiliation>Sanquin Research, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Menage</LastName><ForeName>Charlotte</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Sanquin Research, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jorritsma</LastName><ForeName>Tineke</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Sanquin Research, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Steenhuis</LastName><ForeName>Maurice</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Sanquin Research, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hagen</LastName><ForeName>Ruth R</ForeName><Initials>RR</Initials><AffiliationInfo><Affiliation>Sanquin Research, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van den Dijssel</LastName><ForeName>Jet</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Sanquin Research, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, The Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Jongh</LastName><ForeName>Rivka</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Sanquin Research, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ashhurst</LastName><ForeName>Tom</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Cytometry Core Research Facility, The University of Sydney Charles Perkins Centre, Sydney, New South Wales, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The University of Sydney Faculty of Medicine and Health, Sydney, New South Wales, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Gils</LastName><ForeName>Marit J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Department of Medical Microbiology and Infection Prevention, Amsterdam UMC Location VUmc, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garcia-Vallejo</LastName><ForeName>Juan J</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>Department of Molecular Cell Biology and Immunology, Amsterdam UMC Location VUmc, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Claireaux</LastName><ForeName>Mathieu</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Medical Microbiology and Infection Prevention, Amsterdam UMC Location VUmc, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stalman</LastName><ForeName>Eileen W</ForeName><Initials>EW</Initials><Identifier Source="ORCID">0000-0002-9715-0915</Identifier><AffiliationInfo><Affiliation>Department of Neurology and Neurophysiology, Amsterdam UMC Location AMC, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Dam</LastName><ForeName>Koos P J</ForeName><Initials>KPJ</Initials><Identifier Source="ORCID">0000-0002-2602-4364</Identifier><AffiliationInfo><Affiliation>Department of Neurology and Neurophysiology, Amsterdam UMC Location AMC, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wieske</LastName><ForeName>Luuk</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurophysiology, Amsterdam UMC Location AMC, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Neurophysiology, St Antonius Ziekenhuis, Nieuwegein, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boekel</LastName><ForeName>Laura</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0001-5473-7786</Identifier><AffiliationInfo><Affiliation>Department of Rheumatology, Reade Research, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wolbink</LastName><ForeName>Gertjan</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0003-1924-7460</Identifier><AffiliationInfo><Affiliation>Sanquin Research, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Rheumatology, Reade Research, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tas</LastName><ForeName>Sander W</ForeName><Initials>SW</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Clinical Immunology, Amsterdam Rheumatology and immunology Center, Amsterdam University Medical Centres, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rispens</LastName><ForeName>Theo</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Sanquin Research, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kuijpers</LastName><ForeName>Taco W</ForeName><Initials>TW</Initials><AffiliationInfo><Affiliation>Department of Pediatric Immunology, Amsterdam UMC Location AMC, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eftimov</LastName><ForeName>Filip</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurophysiology, Amsterdam UMC Location AMC, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Ham</LastName><ForeName>Sija Marieke</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>Sanquin Research, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Swammerdam Institute for Life Sciences, University of Amsterdam, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ten Brinke</LastName><ForeName>Anja</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Sanquin Research, Amsterdam, The Netherlands a.tenbrinke@sanquin.nl.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>T2B! Immunity Against SARS-CoV-2 Study Group</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>RMD Open</MedlineTA><NlmUniqueID>101662038</NlmUniqueID><ISSNLinking>2056-5933</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>YL5FZ2Y5U1</RegistryNumber><NameOfSubstance UI="D008727">Methotrexate</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018501">Antirheumatic Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008727" MajorTopicYN="Y">Methotrexate</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015496" MajorTopicYN="Y">CD4-Positive T-Lymphocytes</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="Y">COVID-19 Vaccines</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001172" MajorTopicYN="Y">Arthritis, Rheumatoid</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001402" MajorTopicYN="Y">B-Lymphocytes</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018501" MajorTopicYN="N">Antirheumatic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">B-lymphocytes</Keyword><Keyword MajorTopicYN="N">T-lymphocytes</Keyword><Keyword MajorTopicYN="N">autoimmune diseases</Keyword><Keyword MajorTopicYN="N">methotrexate</Keyword></KeywordList><CoiStatement>Competing interests: FE, GW, SMvH and TWK report (governmental) grants from ZonMw to study immune response after SARS-Cov-2 vaccination in auto-immune diseases. FE also reports grants from Prinses Beatrix Spierfonds, CSL Behring, Kedrion, Terumo BCT, Grifols, Takeda Pharmaceutical and GBS-CIDP Foundation; consulting fees from UCB Pharma and CSl Behring; honoraria from Grifols. All other authors report no disclosures relevant to the manuscript.</CoiStatement><InvestigatorList><Investigator ValidYN="Y"><LastName>Allaart</LastName><ForeName>Renée Cf van</ForeName><Initials>RCV</Initials></Investigator><Investigator ValidYN="Y"><LastName>Baars</LastName><ForeName>Adája E</ForeName><Initials>AE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bekkenk</LastName><ForeName>Marcel W</ForeName><Initials>MW</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bemelman</LastName><ForeName>Frederike J</ForeName><Initials>FJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bosma</LastName><ForeName>Angela L</ForeName><Initials>AL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Broens</LastName><ForeName>Bo</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brusse</LastName><ForeName>Esther</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Busch</LastName><ForeName>Matthias H</ForeName><Initials>MH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cristianawati</LastName><ForeName>Olvi</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Doorn</LastName><ForeName>Pieter A van</ForeName><Initials>PAV</Initials></Investigator><Investigator ValidYN="Y"><LastName>Elias</LastName><ForeName>George</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Els</LastName><ForeName>Cécile Acm van</ForeName><Initials>CAV</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gils</LastName><ForeName>Marit J van</ForeName><Initials>MJV</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stephan Goedee</LastName><ForeName>H</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>D'Haens</LastName><ForeName>Geert Ram</ForeName><Initials>GR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hijnen</LastName><ForeName>Dirk Jan</ForeName><Initials>DJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hilhorst</LastName><ForeName>Marc L</ForeName><Initials>ML</Initials></Investigator><Investigator ValidYN="Y"><LastName>Horváth</LastName><ForeName>Barbara</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jallah</LastName><ForeName>Papay Bp</ForeName><Initials>PB</Initials></Investigator><Investigator ValidYN="Y"><LastName>Löwenberg</LastName><ForeName>Mark</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mirfazeli</LastName><ForeName>Elham S</ForeName><Initials>ES</Initials></Investigator><Investigator ValidYN="Y"><LastName>Musters</LastName><ForeName>Annelie H</ForeName><Initials>AH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Keijser</LastName><ForeName>Jim Bd</ForeName><Initials>JB</Initials></Investigator><Investigator ValidYN="Y"><LastName>Keijzer</LastName><ForeName>Sofie</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Killestein</LastName><ForeName>Joep</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Leeuw</LastName><ForeName>Karina de</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kooi</LastName><ForeName>Anneke J van der</ForeName><Initials>AJV</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ouwerkerk</LastName><ForeName>Lotte van</ForeName><Initials>LV</Initials></Investigator><Investigator ValidYN="Y"><LastName>Paassen</LastName><ForeName>Pieter van</ForeName><Initials>PV</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sanchez</LastName><ForeName>Agner R Parra</ForeName><Initials>ARP</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ludo van der Pol</LastName><ForeName>W</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Post</LastName><ForeName>Nicoline F</ForeName><Initials>NF</Initials></Investigator><Investigator ValidYN="Y"><LastName>Raaphorst</LastName><ForeName>Joost</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ruiter</LastName><ForeName>Annabel M</ForeName><Initials>AM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rutgers</LastName><ForeName>Abraham</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schreurs</LastName><ForeName>Corine Rg</ForeName><Initials>CR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Spuls</LastName><ForeName>Phyllis I</ForeName><Initials>PI</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bart Takkenberg</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Onno Teng</LastName><ForeName>Y K</ForeName><Initials>YK</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vegting</LastName><ForeName>Yosta</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Verschuuren</LastName><ForeName>Jan Jgm</ForeName><Initials>JJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Volkers</LastName><ForeName>Adriaan G</ForeName><Initials>AG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Voskuyl</LastName><ForeName>Alexandre E</ForeName><Initials>AE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wit</LastName><ForeName>Jelle de</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Woude</LastName><ForeName>Diane van der</ForeName><Initials>DV</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zwinderman</LastName><ForeName>Koos Ah</ForeName><Initials>KA</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>6</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>8</Day><Hour>4</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>8</Day><Hour>4</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>7</Day><Hour>22</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>7</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39375177</ArticleId><ArticleId IdType="pmc">PMC11459311</ArticleId><ArticleId IdType="doi">10.1136/rmdopen-2024-004664</ArticleId><ArticleId IdType="pii">rmdopen-2024-004664</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Freeman ML, Clagett BM, Moisi D, et al. Methotrexate Inhibits T Cell Proliferation but Not Inflammatory Cytokine Expression to Modulate Immunity in People Living With HIV. Front Immunol. 2022;13:924718. doi: 10.3389/fimmu.2022.924718.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.924718</ArticleId><ArticleId IdType="pmc">PMC9374564</ArticleId><ArticleId IdType="pubmed">35967371</ArticleId></ArticleIdList></Reference><Reference><Citation>Cronstein BN, Aune TM. Methotrexate and its mechanisms of action in inflammatory arthritis. Nat Rev Rheumatol. 2020;16:145–54. doi: 10.1038/s41584-020-0373-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41584-020-0373-9</ArticleId><ArticleId IdType="pubmed">32066940</ArticleId></ArticleIdList></Reference><Reference><Citation>Kapetanovic MC, Roseman C, Jönsson G, et al. Antibody response is reduced following vaccination with 7-valent conjugate pneumococcal vaccine in adult methotrexate-treated patients with established arthritis, but not those treated with tumor necrosis factor inhibitors. Arthritis Rheum. 2011;63:3723–32. doi: 10.1002/art.30580.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.30580</ArticleId><ArticleId IdType="pubmed">21834061</ArticleId></ArticleIdList></Reference><Reference><Citation>Kapetanovic MC, Nagel J, Nordström I, et al. Methotrexate reduces vaccine-specific immunoglobulin levels but not numbers of circulating antibody-producing B cells in rheumatoid arthritis after vaccination with a conjugate pneumococcal vaccine. Vaccine (Auckl) 2017;35:903–8. doi: 10.1016/j.vaccine.2016.12.068.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2016.12.068</ArticleId><ArticleId IdType="pubmed">28081972</ArticleId></ArticleIdList></Reference><Reference><Citation>Kobie JJ, Zheng B, Bryk P, et al. Decreased influenza-specific B cell responses in rheumatoid arthritis patients treated with anti-tumor necrosis factor. Arthritis Res Ther. 2011;13:R209. doi: 10.1186/ar3542.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/ar3542</ArticleId><ArticleId IdType="pmc">PMC3334662</ArticleId><ArticleId IdType="pubmed">22177419</ArticleId></ArticleIdList></Reference><Reference><Citation>Ribeiro ACM, Guedes LKN, Moraes JCB, et al. Reduced seroprotection after pandemic H1N1 influenza adjuvant-free vaccination in patients with rheumatoid arthritis: implications for clinical practice. Ann Rheum Dis. 2011;70:2144–7. doi: 10.1136/ard.2011.152983.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/ard.2011.152983</ArticleId><ArticleId IdType="pubmed">21859696</ArticleId></ArticleIdList></Reference><Reference><Citation>Boekel L, Steenhuis M, Hooijberg F, et al. Antibody development after COVID-19 vaccination in patients with autoimmune diseases in the Netherlands: a substudy of data from two prospective cohort studies. Lancet Rheumatol . 2021;3:e778–88. doi: 10.1016/S2665-9913(21)00222-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2665-9913(21)00222-8</ArticleId><ArticleId IdType="pmc">PMC8346242</ArticleId><ArticleId IdType="pubmed">34396154</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahil SK, Bechman K, Raharja A, et al. Humoral and cellular immunogenicity to a second dose of COVID-19 vaccine BNT162b2 in people receiving methotrexate or targeted immunosuppression: a longitudinal cohort study. Lancet Rheumatol . 2022;4:e42–52. doi: 10.1016/S2665-9913(21)00333-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2665-9913(21)00333-7</ArticleId><ArticleId IdType="pmc">PMC8577228</ArticleId><ArticleId IdType="pubmed">34778846</ArticleId></ArticleIdList></Reference><Reference><Citation>Shirata M, Ito I, Tanaka M, et al. Impact of methotrexate on humoral and cellular immune responses to SARS-CoV-2 mRNA vaccine in patients with rheumatoid arthritis. Clin Exp Med. 2023;23:4707–20. doi: 10.1007/s10238-023-01163-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10238-023-01163-5</ArticleId><ArticleId IdType="pubmed">37582911</ArticleId></ArticleIdList></Reference><Reference><Citation>Feuchtenberger M, Kovacs MS, Eder A, et al. Methotrexate significantly reduces the humoral vaccination response against SARS-CoV-2 in older but not younger patients with rheumatoid arthritis. Rheumatol Int. 2022;42:959–66. doi: 10.1007/s00296-022-05123-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00296-022-05123-2</ArticleId><ArticleId IdType="pmc">PMC9012944</ArticleId><ArticleId IdType="pubmed">35429290</ArticleId></ArticleIdList></Reference><Reference><Citation>Haberman RH, Herati R, Simon D, et al. Methotrexate hampers immunogenicity to BNT162b2 mRNA COVID-19 vaccine in immune-mediated inflammatory disease. Ann Rheum Dis. 2021;80:1339–44. doi: 10.1136/annrheumdis-2021-220597.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2021-220597</ArticleId><ArticleId IdType="pmc">PMC8219484</ArticleId><ArticleId IdType="pubmed">34035003</ArticleId></ArticleIdList></Reference><Reference><Citation>Sieiro Santos C, Calleja Antolin S, Moriano Morales C, et al. Immune responses to mRNA vaccines against SARS-CoV-2 in patients with immune-mediated inflammatory rheumatic diseases. RMD Open. 2022;8:e001898. doi: 10.1136/rmdopen-2021-001898.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/rmdopen-2021-001898</ArticleId><ArticleId IdType="pmc">PMC9065768</ArticleId><ArticleId IdType="pubmed">34987093</ArticleId></ArticleIdList></Reference><Reference><Citation>Wieske L, van Dam KPJ, Steenhuis M, et al. Humoral responses after second and third SARS-CoV-2 vaccination in patients with immune-mediated inflammatory disorders on immunosuppressants: a cohort study. Lancet Rheumatol . 2022;4:e338–50. doi: 10.1016/S2665-9913(22)00034-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2665-9913(22)00034-0</ArticleId><ArticleId IdType="pmc">PMC8930018</ArticleId><ArticleId IdType="pubmed">35317410</ArticleId></ArticleIdList></Reference><Reference><Citation>Furer V, Eviatar T, Zisman D, et al. Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study. Ann Rheum Dis. 2021;80:1330–8. doi: 10.1136/annrheumdis-2021-220647.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2021-220647</ArticleId><ArticleId IdType="pubmed">34127481</ArticleId></ArticleIdList></Reference><Reference><Citation>Abhishek A, Peckham N, Pade C, et al. Effect of a 2-week interruption in methotrexate treatment on COVID-19 vaccine response in people with immune-mediated inflammatory diseases (VROOM study): a randomised, open label, superiority trial. Lancet Rheumatol. 2024;6:e92–104. doi: 10.1016/S2665-9913(23)00298-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2665-9913(23)00298-9</ArticleId><ArticleId IdType="pubmed">38267107</ArticleId></ArticleIdList></Reference><Reference><Citation>Martínez-Fleta P, Vicente-Rabaneda EF, Triguero-Martínez A, et al. Beneficial effect of temporary methotrexate interruption on B and T cell responses upon SARS-CoV-2 vaccination in patients with rheumatoid arthritis or psoriatic arthritis. NPJ Vaccines. 2024;9:21. doi: 10.1038/s41541-024-00805-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41541-024-00805-3</ArticleId><ArticleId IdType="pmc">PMC10827732</ArticleId><ArticleId IdType="pubmed">38291047</ArticleId></ArticleIdList></Reference><Reference><Citation>Habermann E, Gieselmann L, Tober-Lau P, et al. Pausing methotrexate prevents impairment of Omicron BA.1 and BA.2 neutralisation after COVID-19 booster vaccination. RMD Open. 2022;8:e002639. doi: 10.1136/rmdopen-2022-002639.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/rmdopen-2022-002639</ArticleId><ArticleId IdType="pmc">PMC9556747</ArticleId><ArticleId IdType="pubmed">36216410</ArticleId></ArticleIdList></Reference><Reference><Citation>Wieske L, Stalman EW, van Dam PJK, et al. Persistence of seroconversion at 6 months following primary immunisation in patients with immune-mediated inflammatory diseases. Ann Rheum Dis. 2023;82:883–5. doi: 10.1136/ard-2022-223464.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/ard-2022-223464</ArticleId><ArticleId IdType="pubmed">36720583</ArticleId></ArticleIdList></Reference><Reference><Citation>Haberman RH, Um S, Axelrad JE, et al. Methotrexate and TNF inhibitors affect long-term immunogenicity to COVID-19 vaccination in patients with immune-mediated inflammatory disease. Lancet Rheumatol . 2022;4:e384–7. doi: 10.1016/S2665-9913(22)00069-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2665-9913(22)00069-8</ArticleId><ArticleId IdType="pmc">PMC8975261</ArticleId><ArticleId IdType="pubmed">35403000</ArticleId></ArticleIdList></Reference><Reference><Citation>Klebanoff SD, Rodda LB, Morishima C, et al. Diminished responses to mRNA-based SARS-CoV-2 vaccines in individuals with rheumatoid arthritis on immune-modifying therapies. JCI Insight. 2023;8:e168663. doi: 10.1172/jci.insight.168663.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.168663</ArticleId><ArticleId IdType="pmc">PMC10445680</ArticleId><ArticleId IdType="pubmed">37338983</ArticleId></ArticleIdList></Reference><Reference><Citation>Pincus T, Yazici Y, Bergman MJ. RAPID3, an index to assess and monitor patients with rheumatoid arthritis, without formal joint counts: similar results to DAS28 and CDAI in clinical trials and clinical care. Rheum Dis Clin North Am . 2009;35:773–8. doi: 10.1016/j.rdc.2009.10.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.rdc.2009.10.008</ArticleId><ArticleId IdType="pubmed">19962621</ArticleId></ArticleIdList></Reference><Reference><Citation>Kardava L, Rachmaninoff N, Lau WW, et al. Early human B cell signatures of the primary antibody response to mRNA vaccination. Proc Natl Acad Sci USA. 2022;119 doi: 10.1073/pnas.2204607119.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2204607119</ArticleId><ArticleId IdType="pmc">PMC9282446</ArticleId><ArticleId IdType="pubmed">35759653</ArticleId></ArticleIdList></Reference><Reference><Citation>Ciabattini A, Pastore G, Lucchesi S, et al. Trajectory of Spike-Specific B Cells Elicited by Two Doses of BNT162b2 mRNA Vaccine. Cells. 2023;12:1706. doi: 10.3390/cells12131706.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells12131706</ArticleId><ArticleId IdType="pmc">PMC10340653</ArticleId><ArticleId IdType="pubmed">37443740</ArticleId></ArticleIdList></Reference><Reference><Citation>Zurbuchen Y, Michler J, Taeschler P, et al. Human memory B cells show plasticity and adopt multiple fates upon recall response to SARS-CoV-2. Nat Immunol. 2023;24:955–65. doi: 10.1038/s41590-023-01497-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-023-01497-y</ArticleId><ArticleId IdType="pmc">PMC10232369</ArticleId><ArticleId IdType="pubmed">37106039</ArticleId></ArticleIdList></Reference><Reference><Citation>Avdeeva A, Rubtsov Y, Dyikanov D, et al. Regulatory T cells in patients with early untreated rheumatoid arthritis: Phenotypic changes in the course of methotrexate treatment. Biochimie. 2020;174:9–17. doi: 10.1016/j.biochi.2020.03.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biochi.2020.03.014</ArticleId><ArticleId IdType="pubmed">32275944</ArticleId></ArticleIdList></Reference><Reference><Citation>Cribbs AP, Kennedy A, Penn H, et al. Methotrexate Restores Regulatory T Cell Function Through Demethylation of the FoxP3 Upstream Enhancer in Patients With Rheumatoid Arthritis. Arthritis Rheumatol. 2015;67:1182–92. doi: 10.1002/art.39031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.39031</ArticleId><ArticleId IdType="pubmed">25604080</ArticleId></ArticleIdList></Reference><Reference><Citation>Nived P, Pettersson Å, Jönsson G, et al. Methotrexate reduces circulating Th17 cells and impairs plasmablast and memory B cell expansions following pneumococcal conjugate immunization in RA patients. Sci Rep. 2021;11:9199. doi: 10.1038/s41598-021-88491-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-88491-2</ArticleId><ArticleId IdType="pmc">PMC8080705</ArticleId><ArticleId IdType="pubmed">33911135</ArticleId></ArticleIdList></Reference><Reference><Citation>Guggino G, Giardina A, Ferrante A, et al. The in vitro addition of methotrexate and/or methylprednisolone determines peripheral reduction in Th17 and expansion of conventional Treg and of IL-10 producing Th17 lymphocytes in patients with early rheumatoid arthritis. Rheumatol Int. 2015;35:171–5. doi: 10.1007/s00296-014-3030-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00296-014-3030-2</ArticleId><ArticleId IdType="pubmed">24792332</ArticleId></ArticleIdList></Reference><Reference><Citation>Szalay B, Vásárhelyi B, Cseh A, et al. The impact of conventional DMARD and biological therapies on CD4+ cell subsets in rheumatoid arthritis: a follow-up study. Clin Rheumatol. 2014;33:175–85. doi: 10.1007/s10067-013-2352-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10067-013-2352-x</ArticleId><ArticleId IdType="pubmed">23934385</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X, Miao M, Zhang R, et al. Efficacy and safety of low-dose interleukin-2 in combination with methotrexate in patients with active rheumatoid arthritis: a randomized, double-blind, placebo-controlled phase 2 trial. Sig Transduct Target Ther. 2022;7:67. doi: 10.1038/s41392-022-00887-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-022-00887-2</ArticleId><ArticleId IdType="pmc">PMC8898945</ArticleId><ArticleId IdType="pubmed">35250032</ArticleId></ArticleIdList></Reference><Reference><Citation>Boekel L, Stalman EW, Wieske L, et al. Breakthrough SARS-CoV-2 infections with the delta (B.1.617.2) variant in vaccinated patients with immune-mediated inflammatory diseases using immunosuppressants: a substudy of two prospective cohort studies. Lancet Rheumatol . 2022;4:e417–29. doi: 10.1016/S2665-9913(22)00102-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2665-9913(22)00102-3</ArticleId><ArticleId IdType="pmc">PMC9054068</ArticleId><ArticleId IdType="pubmed">35527808</ArticleId></ArticleIdList></Reference><Reference><Citation>Stalman EW, Wieske L, van Dam KPJ, et al. Breakthrough infections with the SARS-CoV-2 omicron (B.1.1.529) variant in patients with immune-mediated inflammatory diseases. Ann Rheum Dis. 2022;81:1757–66. doi: 10.1136/ard-2022-222904.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/ard-2022-222904</ArticleId><ArticleId IdType="pubmed">36357161</ArticleId></ArticleIdList></Reference><Reference><Citation>McKeigue PM, Porter D, Hollick RJ, et al. Risk of severe COVID-19 in patients with inflammatory rheumatic diseases treated with immunosuppressive therapy in Scotland. Scand J Rheumatol. 2023;52:412–7. doi: 10.1080/03009742.2022.2063376.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/03009742.2022.2063376</ArticleId><ArticleId IdType="pubmed">35549809</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel NJ, Wang X, Fu X, et al. Factors associated with COVID-19 breakthrough infection among vaccinated patients with rheumatic diseases: A cohort study. Semin Arthritis Rheum. 2023;58:S0049-0172(22)00159-7. doi: 10.1016/j.semarthrit.2022.152108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.semarthrit.2022.152108</ArticleId><ArticleId IdType="pmc">PMC9605731</ArticleId><ArticleId IdType="pubmed">36347211</ArticleId></ArticleIdList></Reference><Reference><Citation>Liew J, Gianfrancesco M, Harrison C, et al. SARS-CoV-2 breakthrough infections among vaccinated individuals with rheumatic disease: results from the COVID-19 Global Rheumatology Alliance provider registry. RMD Open. 2022;8:e002187. doi: 10.1136/rmdopen-2021-002187.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/rmdopen-2021-002187</ArticleId><ArticleId IdType="pmc">PMC8987210</ArticleId><ArticleId IdType="pubmed">35387864</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehta P, Sanchez E, Moraitis E, et al. Influenza vaccination and interruption of methotrexate in adult patients in the COVID-19 era: an ongoing dilemma. Lancet Rheumatol . 2021;3:e9–10. doi: 10.1016/S2665-9913(20)30392-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2665-9913(20)30392-1</ArticleId><ArticleId IdType="pmc">PMC7833938</ArticleId><ArticleId IdType="pubmed">33521669</ArticleId></ArticleIdList></Reference><Reference><Citation>Park JK, Lee YJ, Shin K, et al. Impact of temporary methotrexate discontinuation for 2 weeks on immunogenicity of seasonal influenza vaccination in patients with rheumatoid arthritis: a randomised clinical trial. Ann Rheum Dis. 2018;77:898–904. doi: 10.1136/annrheumdis-2018-213222.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2018-213222</ArticleId><ArticleId IdType="pmc">PMC5965360</ArticleId><ArticleId IdType="pubmed">29572291</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>